ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: Before the advent of ABL1 tyrosine kinase inhibitors (TKIs), blasts were usually of myeloid phenotype in approximately 70% of CML-BP patients and of B-Lymphoid phenotype in approximately 30% of patients; rarely, mixed phenotypes were found.